<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02573311</url>
  </required_header>
  <id_info>
    <org_study_id>527.85</org_study_id>
    <nct_id>NCT02573311</nct_id>
  </id_info>
  <brief_title>Actual Use Study of Tamsulosin in Men</brief_title>
  <official_title>A 6-month OTC-simulated, Open Label, Uncontrolled Study of Tamsulosin 0.4 mg in Men</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      An actual use study to assess how men who respond to advertisements about urinary symptoms
      use tamsulosin in a simulated Over the Counter (OTC) setting including following &quot;stop use
      and ask a doctor if&quot; and &quot;ask a doctor before use&quot; statements and if they take the medication
      according to the label instructions, also assess any reported adverse events during simulated
      OTC use.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 23, 2015</start_date>
  <completion_date type="Actual">August 1, 2016</completion_date>
  <primary_completion_date type="Actual">August 1, 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Men Who Report a Condition Listed Under the &quot;Stop Use and Ask a Doctor if&quot; Section of the DFL Within the First 12 Weeks of Using Study Product and do Not Stop Use or Initiate Contact With Doctor Out of Total Population in Cohort 1</measure>
    <time_frame>12 weeks</time_frame>
    <description>Percentage of men who reported a condition listed under the &quot;Stop use and ask a doctor if&quot; section of the Drug Facts Label (DFL) within the first 12 weeks of using study product and did not stop use or initiated contact with a doctor out of the total population is presented along with 95% exact two sided Clopper-Pearson confidence interval.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Men Who Report a Condition Listed Under the &quot;Stop Use and Ask a Doctor if&quot; Section of the DFL During the Study (24 Weeks) and do Not Stop Use or Initiate Contact With a Doctor Out of the Total Population in Cohort 1</measure>
    <time_frame>24 weeks</time_frame>
    <description>Percentage of men who reported a condition listed under the &quot;Stop use and ask a doctor if&quot; section of the DFL during the study (i.e., 24 weeks) and did not stop use or initiated contact with a doctor out of the total population of men in Cohort 1 is presented along with 95% exact two sided Clopper-Pearson confidence interval.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Men Who Report Condition Listed Under &quot;Stop Use and Ask a Doctor if&quot; Section of the DFL and do Not Stop Use or Initiate Contact With Doctor Out of the Total Population in Cohort 1 Who Report the Condition Within 12 Weeks</measure>
    <time_frame>Week 12</time_frame>
    <description>Percentage of men who reported a condition listed under the &quot;Stop use and ask a doctor if&quot; section of the DFL within 12 weeks of using study product and did not stop use or initiated contact with a doctor out of the total population of men in Cohort 1 who reported a condition listed under the &quot;Stop use and ask a doctor if&quot; section of the DFL within 12 weeks of using study product is presented along with 95% exact two sided Clopper-Pearson confidence interval.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Men Who Report Condition Listed Under &quot;Stop Use and Ask a Doctor if&quot; Section of the DFL and do Not Stop Use or Initiate Contact With Doctor Out of the Total Population in Cohort 1 Who Report the Condition Within 24 Weeks</measure>
    <time_frame>Week 24</time_frame>
    <description>Percentage of men who reported a condition listed under the &quot;Stop use and ask a doctor if&quot; section of the DFL within 24 weeks of using study product and did not stop use or initiated contact with a doctor out of the total population of men in Cohort 1 who reported a condition listed under the &quot;Stop use and ask a doctor if&quot; section of the DFL within 24 weeks of using study product is presented along with 95% exact two sided Clopper-Pearson confidence interval.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Men Who Report a Condition Listed Under the &quot;Stop Use and Ask a Doctor if&quot; Section of the DFL Within the First 12 Weeks of Using Study Product Out of the Total Population in Cohort 1</measure>
    <time_frame>12 weeks</time_frame>
    <description>Percentage of men who reported a condition listed under the &quot;Stop use and ask a doctor if&quot; section of the DFL within the first 12 weeks of using the study product out of the total population of men in Cohort 1 is presented along with 95% exact two sided Clopper-Pearson confidence interval</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Men Who Report at Baseline a Symptom or Condition Under the &quot;Ask A Doctor Before Use&quot; Section of the DFL and Initiate Contact With a Doctor Out of the Total Population in Cohort 1</measure>
    <time_frame>24 weeks</time_frame>
    <description>Percentage of men who reported at baseline a symptom or condition under the &quot;Ask A Doctor Before Use&quot; section of the DFL and initiated contact with a doctor out of the total population of men in Cohort 1 is presented along with 95% exact two sided Clopper-Pearson confidence interval.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Men Who Report at Baseline a Symptom or Condition Under the &quot;Ask A Doctor Before Use&quot; Section of the DFL and Initiate Contact With a Doctor Out of the Total Population of Cohort 1 Who Report a Symptom or Condition</measure>
    <time_frame>24 weeks</time_frame>
    <description>Percentage of men who reported at baseline a symptom or condition under the &quot;Ask A Doctor Before Use&quot; section of the DFL and initiated contact with a doctor out of the total population of men in Cohort 1 who reported a symptom or condition is presented along with 95% exact two sided Clopper-Pearson confidence interval.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Men Who Seek the Advice of a Physician Within the First 12/24 Weeks of the Study Out of the Total Population in Cohort 1</measure>
    <time_frame>Week 12 and Week 24</time_frame>
    <description>Percentage of men who sought advice of a physician within the first 12/24 weeks of the study out of the total population of men in Cohort 1 is presented along with 95% exact two sided Clopper-Pearson confidence interval</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Men Who Took Two or More Capsules Per Day Within the First 12/24 Weeks of Using Study Product Out of the Total Population in Cohort 1</measure>
    <time_frame>Week 12 and Week 24</time_frame>
    <description>Percentage of men who took two or more capsules per day within the first 12/24 weeks of using study product out of the total population of men in Cohort 1 is presented along with 95% exact two sided Clopper-Pearson confidence interval</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">1117</enrollment>
  <condition>Urological Manifestations</condition>
  <arm_group>
    <arm_group_label>men</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tamsulosin hydrochloride</intervention_name>
    <arm_group_label>men</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Men, 18 years of age and older, with bothersome urinary symptoms

          -  Able to speak, read and understand English

          -  Subject or anyone in their household is not currently employed by a marketing or
             marketing research company, advertising agency or public relations firm, a pharmacy or
             pharmaceutical company, a manufacturer of medicines, a managed care or health
             insurance company, as a certified or licensed healthcare professional or in a
             healthcare practice

          -  Has not participated in any clinical trial in the last 12 months

          -  Willing to sign an informed consent/HIPPA form and willing and able to provide contact
             information

        Exclusion criteria:

          -  Allergy to tamsulosin hydrochloride or sulpha drugs

          -  Report current use of a medication listed on the &quot;Do not use&quot; section of the Drug
             Facts Label (DFL)

          -  Choose not to purchase the study product

          -  Do not provide consent or sign HIPPA form

          -  Do not provide contact information
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Parkway Discount Drugs</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Homewood Pharmacy</name>
      <address>
        <city>Homewood</city>
        <state>Alabama</state>
        <zip>35209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Robert's Discount Pharmacy</name>
      <address>
        <city>Hoover</city>
        <state>Alabama</state>
        <zip>35226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pharmacy at the Pig</name>
      <address>
        <city>McCalla</city>
        <state>Alabama</state>
        <zip>35111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pinson Discount Drugs</name>
      <address>
        <city>Pinson</city>
        <state>Alabama</state>
        <zip>35126</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ACACIA Apothecary and Wellness</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85704</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Parkview Compounding Pharmacy</name>
      <address>
        <city>Rancho Cucamonga</city>
        <state>California</state>
        <zip>91730</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Garden Drug</name>
      <address>
        <city>Fort Lauderdale</city>
        <state>Florida</state>
        <zip>33309</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pill Box Pharmacy</name>
      <address>
        <city>Pembroke Pines</city>
        <state>Florida</state>
        <zip>33026</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sutton Family Pharmacy</name>
      <address>
        <city>Dalton</city>
        <state>Georgia</state>
        <zip>30721</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Huff's Drug Store</name>
      <address>
        <city>Ellijay</city>
        <state>Georgia</state>
        <zip>30540</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wynn's Pharmacy Incorporated</name>
      <address>
        <city>Griffin</city>
        <state>Georgia</state>
        <zip>30224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Family Care Pharmacy</name>
      <address>
        <city>Highland</city>
        <state>Illinois</state>
        <zip>62249</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Goodrich Pharmacy</name>
      <address>
        <city>Andover</city>
        <state>Minnesota</state>
        <zip>55304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Goodrich Pharmacy</name>
      <address>
        <city>Blaine</city>
        <state>Minnesota</state>
        <zip>55434</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Goodrich Pharmacy</name>
      <address>
        <city>Elk River</city>
        <state>Minnesota</state>
        <zip>55330</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northfield Pharmacy</name>
      <address>
        <city>Northfield</city>
        <state>Minnesota</state>
        <zip>55057</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cub Pharmacy #1924</name>
      <address>
        <city>Saint Louis Park</city>
        <state>Minnesota</state>
        <zip>55426</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Medicine Shoppe and Elsberry Pharmacy</name>
      <address>
        <city>Elsberry</city>
        <state>Missouri</state>
        <zip>63343</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Albers' Specialty Pharmacy</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Apex Specialty Pharmacy</name>
      <address>
        <city>Riverside</city>
        <state>Missouri</state>
        <zip>64150</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stevenson Family Pharmacy</name>
      <address>
        <city>Saint Joseph</city>
        <state>Missouri</state>
        <zip>64504</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Countryside Pharmacy</name>
      <address>
        <city>Savannah</city>
        <state>Missouri</state>
        <zip>64485</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Road Pharmacy</name>
      <address>
        <city>Monroe</city>
        <state>New Jersey</state>
        <zip>08831</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duran Central Pharmacy</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sam's Regent Pharmacy</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Total Care Pharmacy</name>
      <address>
        <city>Burlington</city>
        <state>North Carolina</state>
        <zip>27215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kroger Pharmacy #342</name>
      <address>
        <city>Cary</city>
        <state>North Carolina</state>
        <zip>27513</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charleston Pharmacy, South Charleston</name>
      <address>
        <city>South Charleston</city>
        <state>Ohio</state>
        <zip>45368</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Med Center Compounding Pharmacy &amp; Health Center</name>
      <address>
        <city>Cleveland</city>
        <state>Tennessee</state>
        <zip>37311</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>T.B. Bond Pharmacy</name>
      <address>
        <city>Hillsboro</city>
        <state>Texas</state>
        <zip>76645</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eagle Pharmacy</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77099</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mountain West Apothecary</name>
      <address>
        <city>Bountiful</city>
        <state>Utah</state>
        <zip>84010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maple Mountain Pharmacy</name>
      <address>
        <city>Mapleton</city>
        <state>Utah</state>
        <zip>84664</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Medicine Shoppe</name>
      <address>
        <city>Ogden</city>
        <state>Utah</state>
        <zip>84401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Family Plaza Pharmacy</name>
      <address>
        <city>West Jordan</city>
        <state>Utah</state>
        <zip>84088</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Foothills Compounding Pharmacy</name>
      <address>
        <city>Enumclaw</city>
        <state>Washington</state>
        <zip>98022</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kelley-Ross Compounding Pharmacy</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rxtra Care</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kusler's Compounding Pharmacy</name>
      <address>
        <city>Snohomish</city>
        <state>Washington</state>
        <zip>98290</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://trials.boehringer-ingelheim.com</url>
    <description>Synopsis Link</description>
  </link>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>October 1, 2015</study_first_submitted>
  <study_first_submitted_qc>October 8, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 9, 2015</study_first_posted>
  <results_first_submitted>March 12, 2020</results_first_submitted>
  <results_first_submitted_qc>April 6, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">April 8, 2020</results_first_posted>
  <last_update_submitted>April 6, 2020</last_update_submitted>
  <last_update_submitted_qc>April 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urological Manifestations</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tamsulosin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>The trial consisted of 2 parts. One was the product review phase (Part 1) and another was the actual use phase (Part 2). The number of enrolled patients in the protocol represent the number of participants (1117) who intended to purchase study product and enter part 2 of the study. All endpoints are based on part 2 of the study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Cohort 1</title>
          <description>Cohort 1 included all men who were not currently using a prescription medicine for Benign Prostatic Hyperplasia (BPH) and answered the purchase question for the study product (FLOMAX® (tamsulosin hydrochloride) 0.4 milligram (mg) capsules for self-directed use orally for a period of 24 weeks).</description>
        </group>
        <group group_id="P2">
          <title>Cohort 2</title>
          <description>Cohort 2 included all men who were currently using a prescription medicine for Benign Prostatic Hyperplasia (BPH) and answered the purchase question for the study product (FLOMAX® (tamsulosin hydrochloride) 0.4 milligram (mg) capsules for self-directed use orally for a period of 24 weeks).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Disposition for Part 1</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1737">Started are subjects who entered Part 1 and answered the purchase question</participants>
                <participants group_id="P2" count="364">Started are subjects who entered Part 1 and answered the purchase question</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1730">Completed are the subjects who actually completed Part 1</participants>
                <participants group_id="P2" count="361">Completed are the subjects who actually completed Part 1</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Disposition for Part 2</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="964">Started are subjects who purchased study product and are eligible to enter Part-2 of study.</participants>
                <participants group_id="P2" count="153">Started are subjects who purchased study product and are eligible to enter Part-2 of study.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="754">Completed are the subjects who completed use phase Part-2 (Week 24 and EOS-P2 interviews).</participants>
                <participants group_id="P2" count="127">Completed are the subjects who completed use phase Part-2 (Week 24 and EOS-P2 interviews).</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="210"/>
                <participants group_id="P2" count="26"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="36"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="76"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="60"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Investigator decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other than specified above</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Analysis Set for Cohort 1 and 2: This set included all men who were currently not using a prescription medicine for BPH (Cohort 1) or were currently using a prescription medicine for BPH (Cohort 2) and who answered the purchase question in Part 1. (Age is missing for 8 men)</population>
      <group_list>
        <group group_id="B1">
          <title>Cohort 1</title>
          <description>Cohort 1 included all men who were not currently using a prescription medicine for Benign Prostatic Hyperplasia (BPH) and answered the purchase question for the study product (FLOMAX® (tamsulosin hydrochloride) 0.4 milligram (mg) capsules for self-directed use orally for a period of 24 weeks).</description>
        </group>
        <group group_id="B2">
          <title>Cohort 2</title>
          <description>Cohort 2 included all men who were currently using a prescription medicine for Benign Prostatic Hyperplasia (BPH) and answered the purchase question for the study product (FLOMAX® (tamsulosin hydrochloride) 0.4 milligram (mg) capsules for self-directed use orally for a period of 24 weeks).</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1731"/>
            <count group_id="B2" value="362"/>
            <count group_id="B3" value="2093"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61.8" spread="11.67"/>
                    <measurement group_id="B2" value="68.3" spread="9.10"/>
                    <measurement group_id="B3" value="63.0" spread="11.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1731"/>
                    <measurement group_id="B2" value="362"/>
                    <measurement group_id="B3" value="2093"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Men Who Report a Condition Listed Under the &quot;Stop Use and Ask a Doctor if&quot; Section of the DFL Within the First 12 Weeks of Using Study Product and do Not Stop Use or Initiate Contact With Doctor Out of Total Population in Cohort 1</title>
        <description>Percentage of men who reported a condition listed under the &quot;Stop use and ask a doctor if&quot; section of the Drug Facts Label (DFL) within the first 12 weeks of using study product and did not stop use or initiated contact with a doctor out of the total population is presented along with 95% exact two sided Clopper-Pearson confidence interval.</description>
        <time_frame>12 weeks</time_frame>
        <population>Full Analysis Set for Actual Use (FAS-AU1) included all men who were currently not using a prescription medicine for BPH, purchased the study product, took at least one dose of study drug within the first 12 weeks of purchase and participated in at least 1 phone interview within the first 12 weeks of using the study product.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1</title>
            <description>Cohort 1 included all men who were not currently using a prescription medicine for Benign Prostatic Hyperplasia (BPH) and answered the purchase question for the study product (FLOMAX® (tamsulosin hydrochloride) 0.4 milligram (mg) capsules for self-directed use orally for a period of 24 weeks).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Men Who Report a Condition Listed Under the &quot;Stop Use and Ask a Doctor if&quot; Section of the DFL Within the First 12 Weeks of Using Study Product and do Not Stop Use or Initiate Contact With Doctor Out of Total Population in Cohort 1</title>
          <description>Percentage of men who reported a condition listed under the &quot;Stop use and ask a doctor if&quot; section of the Drug Facts Label (DFL) within the first 12 weeks of using study product and did not stop use or initiated contact with a doctor out of the total population is presented along with 95% exact two sided Clopper-Pearson confidence interval.</description>
          <population>Full Analysis Set for Actual Use (FAS-AU1) included all men who were currently not using a prescription medicine for BPH, purchased the study product, took at least one dose of study drug within the first 12 weeks of purchase and participated in at least 1 phone interview within the first 12 weeks of using the study product.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="924"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2" lower_limit="0.0" upper_limit="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Men Who Report a Condition Listed Under the &quot;Stop Use and Ask a Doctor if&quot; Section of the DFL During the Study (24 Weeks) and do Not Stop Use or Initiate Contact With a Doctor Out of the Total Population in Cohort 1</title>
        <description>Percentage of men who reported a condition listed under the &quot;Stop use and ask a doctor if&quot; section of the DFL during the study (i.e., 24 weeks) and did not stop use or initiated contact with a doctor out of the total population of men in Cohort 1 is presented along with 95% exact two sided Clopper-Pearson confidence interval.</description>
        <time_frame>24 weeks</time_frame>
        <population>FAS AU1</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1</title>
            <description>Cohort 1 included all men who were not currently using a prescription medicine for Benign Prostatic Hyperplasia (BPH) and answered the purchase question for the study product (FLOMAX® (tamsulosin hydrochloride) 0.4 milligram (mg) capsules for self-directed use orally for a period of 24 weeks).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Men Who Report a Condition Listed Under the &quot;Stop Use and Ask a Doctor if&quot; Section of the DFL During the Study (24 Weeks) and do Not Stop Use or Initiate Contact With a Doctor Out of the Total Population in Cohort 1</title>
          <description>Percentage of men who reported a condition listed under the &quot;Stop use and ask a doctor if&quot; section of the DFL during the study (i.e., 24 weeks) and did not stop use or initiated contact with a doctor out of the total population of men in Cohort 1 is presented along with 95% exact two sided Clopper-Pearson confidence interval.</description>
          <population>FAS AU1</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="924"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2" lower_limit="0.0" upper_limit="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Men Who Report Condition Listed Under &quot;Stop Use and Ask a Doctor if&quot; Section of the DFL and do Not Stop Use or Initiate Contact With Doctor Out of the Total Population in Cohort 1 Who Report the Condition Within 12 Weeks</title>
        <description>Percentage of men who reported a condition listed under the &quot;Stop use and ask a doctor if&quot; section of the DFL within 12 weeks of using study product and did not stop use or initiated contact with a doctor out of the total population of men in Cohort 1 who reported a condition listed under the &quot;Stop use and ask a doctor if&quot; section of the DFL within 12 weeks of using study product is presented along with 95% exact two sided Clopper-Pearson confidence interval.</description>
        <time_frame>Week 12</time_frame>
        <population>Full Analysis Set for Actual Use and Stop Use and Ask If – Condition Within the First 12 Weeks: (FAS-AU1-COND12): These populations are subsets of the FAS-AU1 population which will include all men who report a condition listed under the “Stop use and ask a doctor if” section of DFL within the first 12 weeks of using the study product.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1</title>
            <description>Cohort 1 included all men who were not currently using a prescription medicine for Benign Prostatic Hyperplasia (BPH) and answered the purchase question for the study product (FLOMAX® (tamsulosin hydrochloride) 0.4 milligram (mg) capsules for self-directed use orally for a period of 24 weeks).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Men Who Report Condition Listed Under &quot;Stop Use and Ask a Doctor if&quot; Section of the DFL and do Not Stop Use or Initiate Contact With Doctor Out of the Total Population in Cohort 1 Who Report the Condition Within 12 Weeks</title>
          <description>Percentage of men who reported a condition listed under the &quot;Stop use and ask a doctor if&quot; section of the DFL within 12 weeks of using study product and did not stop use or initiated contact with a doctor out of the total population of men in Cohort 1 who reported a condition listed under the &quot;Stop use and ask a doctor if&quot; section of the DFL within 12 weeks of using study product is presented along with 95% exact two sided Clopper-Pearson confidence interval.</description>
          <population>Full Analysis Set for Actual Use and Stop Use and Ask If – Condition Within the First 12 Weeks: (FAS-AU1-COND12): These populations are subsets of the FAS-AU1 population which will include all men who report a condition listed under the “Stop use and ask a doctor if” section of DFL within the first 12 weeks of using the study product.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="207"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" lower_limit="0.1" upper_limit="3.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Men Who Report Condition Listed Under &quot;Stop Use and Ask a Doctor if&quot; Section of the DFL and do Not Stop Use or Initiate Contact With Doctor Out of the Total Population in Cohort 1 Who Report the Condition Within 24 Weeks</title>
        <description>Percentage of men who reported a condition listed under the &quot;Stop use and ask a doctor if&quot; section of the DFL within 24 weeks of using study product and did not stop use or initiated contact with a doctor out of the total population of men in Cohort 1 who reported a condition listed under the &quot;Stop use and ask a doctor if&quot; section of the DFL within 24 weeks of using study product is presented along with 95% exact two sided Clopper-Pearson confidence interval.</description>
        <time_frame>Week 24</time_frame>
        <population>Full Analysis Set for Actual Use and Stop Use and Ask If – Condition Within the First 24 Weeks: (FAS-AU1-COND24): These populations are subsets of the FAS-AU1 population which will include all men who report a condition listed under the “Stop use and ask a doctor if” section of DFL within the first 24 weeks of using the study product.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1</title>
            <description>Cohort 1 included all men who were not currently using a prescription medicine for Benign Prostatic Hyperplasia (BPH) and answered the purchase question for the study product (FLOMAX® (tamsulosin hydrochloride) 0.4 milligram (mg) capsules for self-directed use orally for a period of 24 weeks).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Men Who Report Condition Listed Under &quot;Stop Use and Ask a Doctor if&quot; Section of the DFL and do Not Stop Use or Initiate Contact With Doctor Out of the Total Population in Cohort 1 Who Report the Condition Within 24 Weeks</title>
          <description>Percentage of men who reported a condition listed under the &quot;Stop use and ask a doctor if&quot; section of the DFL within 24 weeks of using study product and did not stop use or initiated contact with a doctor out of the total population of men in Cohort 1 who reported a condition listed under the &quot;Stop use and ask a doctor if&quot; section of the DFL within 24 weeks of using study product is presented along with 95% exact two sided Clopper-Pearson confidence interval.</description>
          <population>Full Analysis Set for Actual Use and Stop Use and Ask If – Condition Within the First 24 Weeks: (FAS-AU1-COND24): These populations are subsets of the FAS-AU1 population which will include all men who report a condition listed under the “Stop use and ask a doctor if” section of DFL within the first 24 weeks of using the study product.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="215"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9" lower_limit="0.1" upper_limit="3.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Men Who Report a Condition Listed Under the &quot;Stop Use and Ask a Doctor if&quot; Section of the DFL Within the First 12 Weeks of Using Study Product Out of the Total Population in Cohort 1</title>
        <description>Percentage of men who reported a condition listed under the &quot;Stop use and ask a doctor if&quot; section of the DFL within the first 12 weeks of using the study product out of the total population of men in Cohort 1 is presented along with 95% exact two sided Clopper-Pearson confidence interval</description>
        <time_frame>12 weeks</time_frame>
        <population>FAS AU1</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1</title>
            <description>Cohort 1 included all men who were not currently using a prescription medicine for Benign Prostatic Hyperplasia (BPH) and answered the purchase question for the study product (FLOMAX® (tamsulosin hydrochloride) 0.4 milligram (mg) capsules for self-directed use orally for a period of 24 weeks).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Men Who Report a Condition Listed Under the &quot;Stop Use and Ask a Doctor if&quot; Section of the DFL Within the First 12 Weeks of Using Study Product Out of the Total Population in Cohort 1</title>
          <description>Percentage of men who reported a condition listed under the &quot;Stop use and ask a doctor if&quot; section of the DFL within the first 12 weeks of using the study product out of the total population of men in Cohort 1 is presented along with 95% exact two sided Clopper-Pearson confidence interval</description>
          <population>FAS AU1</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="924"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.4" lower_limit="19.8" upper_limit="25.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Men Who Report at Baseline a Symptom or Condition Under the &quot;Ask A Doctor Before Use&quot; Section of the DFL and Initiate Contact With a Doctor Out of the Total Population in Cohort 1</title>
        <description>Percentage of men who reported at baseline a symptom or condition under the &quot;Ask A Doctor Before Use&quot; section of the DFL and initiated contact with a doctor out of the total population of men in Cohort 1 is presented along with 95% exact two sided Clopper-Pearson confidence interval.</description>
        <time_frame>24 weeks</time_frame>
        <population>FAS AU1</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1</title>
            <description>Cohort 1 included all men who were not currently using a prescription medicine for Benign Prostatic Hyperplasia (BPH) and answered the purchase question for the study product (FLOMAX® (tamsulosin hydrochloride) 0.4 milligram (mg) capsules for self-directed use orally for a period of 24 weeks).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Men Who Report at Baseline a Symptom or Condition Under the &quot;Ask A Doctor Before Use&quot; Section of the DFL and Initiate Contact With a Doctor Out of the Total Population in Cohort 1</title>
          <description>Percentage of men who reported at baseline a symptom or condition under the &quot;Ask A Doctor Before Use&quot; section of the DFL and initiated contact with a doctor out of the total population of men in Cohort 1 is presented along with 95% exact two sided Clopper-Pearson confidence interval.</description>
          <population>FAS AU1</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="924"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.3" lower_limit="17.8" upper_limit="23.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Men Who Report at Baseline a Symptom or Condition Under the &quot;Ask A Doctor Before Use&quot; Section of the DFL and Initiate Contact With a Doctor Out of the Total Population of Cohort 1 Who Report a Symptom or Condition</title>
        <description>Percentage of men who reported at baseline a symptom or condition under the &quot;Ask A Doctor Before Use&quot; section of the DFL and initiated contact with a doctor out of the total population of men in Cohort 1 who reported a symptom or condition is presented along with 95% exact two sided Clopper-Pearson confidence interval.</description>
        <time_frame>24 weeks</time_frame>
        <population>Full Analysis Set for Actual Use and Ask a Doctor Before Use (FAS-AU1-ASK) is a subset of the FAS-AU1 population which included all men who reported a symptom or condition listed under the “Ask a doctor before use” section of the DFL.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1</title>
            <description>Cohort 1 included all men who were not currently using a prescription medicine for Benign Prostatic Hyperplasia (BPH) and answered the purchase question for the study product (FLOMAX® (tamsulosin hydrochloride) 0.4 milligram (mg) capsules for self-directed use orally for a period of 24 weeks).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Men Who Report at Baseline a Symptom or Condition Under the &quot;Ask A Doctor Before Use&quot; Section of the DFL and Initiate Contact With a Doctor Out of the Total Population of Cohort 1 Who Report a Symptom or Condition</title>
          <description>Percentage of men who reported at baseline a symptom or condition under the &quot;Ask A Doctor Before Use&quot; section of the DFL and initiated contact with a doctor out of the total population of men in Cohort 1 who reported a symptom or condition is presented along with 95% exact two sided Clopper-Pearson confidence interval.</description>
          <population>Full Analysis Set for Actual Use and Ask a Doctor Before Use (FAS-AU1-ASK) is a subset of the FAS-AU1 population which included all men who reported a symptom or condition listed under the “Ask a doctor before use” section of the DFL.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="223"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84.3" lower_limit="78.9" upper_limit="88.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Men Who Seek the Advice of a Physician Within the First 12/24 Weeks of the Study Out of the Total Population in Cohort 1</title>
        <description>Percentage of men who sought advice of a physician within the first 12/24 weeks of the study out of the total population of men in Cohort 1 is presented along with 95% exact two sided Clopper-Pearson confidence interval</description>
        <time_frame>Week 12 and Week 24</time_frame>
        <population>FAS AU1</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1</title>
            <description>Cohort 1 included all men who were not currently using a prescription medicine for Benign Prostatic Hyperplasia (BPH) and answered the purchase question for the study product (FLOMAX® (tamsulosin hydrochloride) 0.4 milligram (mg) capsules for self-directed use orally for a period of 24 weeks).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Men Who Seek the Advice of a Physician Within the First 12/24 Weeks of the Study Out of the Total Population in Cohort 1</title>
          <description>Percentage of men who sought advice of a physician within the first 12/24 weeks of the study out of the total population of men in Cohort 1 is presented along with 95% exact two sided Clopper-Pearson confidence interval</description>
          <population>FAS AU1</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="924"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 12 (N=924)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.1" lower_limit="39.9" upper_limit="46.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24 (N=924)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.4" lower_limit="53.1" upper_limit="59.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Men Who Took Two or More Capsules Per Day Within the First 12/24 Weeks of Using Study Product Out of the Total Population in Cohort 1</title>
        <description>Percentage of men who took two or more capsules per day within the first 12/24 weeks of using study product out of the total population of men in Cohort 1 is presented along with 95% exact two sided Clopper-Pearson confidence interval</description>
        <time_frame>Week 12 and Week 24</time_frame>
        <population>FAS AU1</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1</title>
            <description>Cohort 1 included all men who were not currently using a prescription medicine for Benign Prostatic Hyperplasia (BPH) and answered the purchase question for the study product (FLOMAX® (tamsulosin hydrochloride) 0.4 milligram (mg) capsules for self-directed use orally for a period of 24 weeks).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Men Who Took Two or More Capsules Per Day Within the First 12/24 Weeks of Using Study Product Out of the Total Population in Cohort 1</title>
          <description>Percentage of men who took two or more capsules per day within the first 12/24 weeks of using study product out of the total population of men in Cohort 1 is presented along with 95% exact two sided Clopper-Pearson confidence interval</description>
          <population>FAS AU1</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="924"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 12 (N=924)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.6" lower_limit="6.3" upper_limit="10.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24 (N=924)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.5" lower_limit="8.1" upper_limit="12.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From the first drug administration until 3 days after the treatment phase, up to 171 days.</time_frame>
      <desc>The Treated Set for Cohort (TS) included all men who were currently not using a prescription medicine for BPH (TS1) or were currently using a prescription medicine for BPH (TS2), purchased the study product and took at least one dose of study drug.</desc>
      <group_list>
        <group group_id="E1">
          <title>Cohort 1</title>
          <description>Cohort 1 included all men who were not currently using a prescription medicine for Benign Prostatic Hyperplasia (BPH) and answered the purchase question for the study product (FLOMAX® (tamsulosin hydrochloride) 0.4 milligram (mg) capsules for self-directed use orally for a period of 24 weeks). (TS1)</description>
        </group>
        <group group_id="E2">
          <title>Cohort 2</title>
          <description>Cohort 2 included all men who were currently using a prescription medicine for Benign Prostatic Hyperplasia (BPH) and answered the purchase question for the study product (FLOMAX® (tamsulosin hydrochloride) 0.4 milligram (mg) capsules for self-directed use orally for a period of 24 weeks). (TS2)</description>
        </group>
        <group group_id="E3">
          <title>Cohort 1 and 2</title>
          <description>Cohort 1 and 2 included all men who answered the purchase question for the study product (FLOMAX® (tamsulosin hydrochloride) 0.4 milligram (mg) capsules for self-directed use orally for a period of 24 weeks) regardless of whether they were currently using the product or not. (TS)</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 18.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="54" subjects_at_risk="927"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="150"/>
                <counts group_id="E3" subjects_affected="66" subjects_at_risk="1077"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="927"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1077"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="927"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1077"/>
              </event>
              <event>
                <sub_title>Cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="927"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1077"/>
              </event>
              <event>
                <sub_title>Cardiovascular disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="927"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1077"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="927"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1077"/>
              </event>
              <event>
                <sub_title>Coronary artery occlusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="927"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1077"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="927"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="1077"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Glaucoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="927"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1077"/>
              </event>
              <event>
                <sub_title>Retinal detachment</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="927"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1077"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="927"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1077"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="927"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1077"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="927"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="1077"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="927"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1077"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Anal abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="927"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1077"/>
              </event>
              <event>
                <sub_title>Appendicitis perforated</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="927"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1077"/>
              </event>
              <event>
                <sub_title>Bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="927"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1077"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="927"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1077"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="927"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1077"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="927"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1077"/>
              </event>
              <event>
                <sub_title>Pneumonia bacterial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="927"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1077"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="927"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1077"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="927"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1077"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="927"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1077"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Craniocerebral injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="927"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1077"/>
              </event>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="927"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1077"/>
              </event>
              <event>
                <sub_title>Jaw fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="927"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1077"/>
              </event>
              <event>
                <sub_title>Tendon rupture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="927"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1077"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="927"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1077"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="927"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1077"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="927"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1077"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="927"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1077"/>
              </event>
              <event>
                <sub_title>Bladder cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="927"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1077"/>
              </event>
              <event>
                <sub_title>Chronic lymphocytic leukaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="927"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1077"/>
              </event>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="927"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1077"/>
              </event>
              <event>
                <sub_title>Hepatic cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="927"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1077"/>
              </event>
              <event>
                <sub_title>Lung neoplasm malignant</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="927"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1077"/>
              </event>
              <event>
                <sub_title>Malignant melanoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="927"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1077"/>
              </event>
              <event>
                <sub_title>Pancreatic carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="927"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1077"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="927"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="1077"/>
              </event>
              <event>
                <sub_title>Skin cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="927"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1077"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="927"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1077"/>
              </event>
              <event>
                <sub_title>Throat cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="927"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1077"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Carotid artery disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="927"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1077"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="927"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1077"/>
              </event>
              <event>
                <sub_title>Ischaemic stroke</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="927"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1077"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="927"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1077"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="927"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1077"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="927"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1077"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Calculus urinary</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="927"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1077"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Benign prostatic hyperplasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="927"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1077"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="927"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1077"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="927"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1077"/>
              </event>
              <event>
                <sub_title>Respiratory arrest</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="927"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1077"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetic ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="927"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1077"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Hospitalisation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="927"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1077"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Aortic aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="927"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1077"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="927"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1077"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="927"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1077"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="927"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1077"/>
              </event>
              <event>
                <sub_title>Orthostatic hypotension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="927"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1077"/>
              </event>
              <event>
                <sub_title>Peripheral arterial occlusive disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="927"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1077"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 18.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="61" subjects_at_risk="927"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="150"/>
                <counts group_id="E3" subjects_affected="86" subjects_at_risk="1077"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="48" subjects_at_risk="927"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="150"/>
                <counts group_id="E3" subjects_affected="65" subjects_at_risk="1077"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="927"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="150"/>
                <counts group_id="E3" subjects_affected="23" subjects_at_risk="1077"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI’s intellectual property rights.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Boehringer Ingelheim, Call Center</name_or_title>
      <organization>Boehringer Ingelheim</organization>
      <phone>1-800-243-0127</phone>
      <email>clintriage.rdg@boehringer-ingelheim.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

